Allotera

Allotera Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation, allogeneic CAR-T cell therapies for cancer. Their proprietary gene-editing platform aims to create scalable, off-the-shelf treatments with biologics-like cost margins.